Document is current
Any future updates will be listed below
-
Authors
Chin, Wee Loong https://orcid.org/0000-0002-2549-3601
Zemek, Rachael M. https://orcid.org/0000-0002-0976-6163
Tilsed, Caitlin M.
Forrest, Alistair R. R.
Fear, Vanessa S.
Forbes, Catherine
Boon, Louis
Bosco, Anthony
Guo, Belinda B.
Millward, Michael J.
Nowak, Anna K.
Lake, Richard A.
Lesterhuis, W. Joost
Lassmann, Timo https://orcid.org/0000-0002-0138-2691
-
Funding
Funding for this research was provided by:
Feilman Foundation Fellowship
Raine Medical Research Foundation
Forrest Prospect Fellowship
Department of Health | National Health and Medical Research Council (APP1154524)
Cancer Council Western Australia
- License Information
-
More Information
Article History
Received: 20 June 2023
Accepted: 23 April 2024
First Online: 3 May 2024
Competing interests
: W.J.L.: consultancy Douglas Pharmaceuticals, MSD, research funding Douglas Pharmaceuticals, AstraZeneca. A.K.N. advisory boards Boehringer Ingelheim, Bayer, Roche, BMS; research funding from AstraZeneca. M.M.: Advisory boards MSD, BMS, Roche, AstraZeneca. A.B.: Founder and equity holder of the startup company INSiGENe Pty Ltd that is related to this work. A.B. is a co-founder, equity holder and directory of the startup company Respiradigm Pty Ltd that is unrelated to this work.
